Alpha 2.0
Login Register
» Articles » PMID: 3674850

In Vitro Synergistic Activity Between Bismuth Subcitrate and Various Antimicrobial Agents Against Campylobacter Pyloridis (C. Pylori)

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 1987 Sep 1
PMID 3674850
Citations 17
Authors
D L Van Caekenberghe
J Breyssens
Affiliations
Soon will be listed here.
Abstract

The in vitro interactions between bismuth subcitrate and a variety of antimicrobial agents against 12 Campylobacter pyloridis (C. pylori) isolates were studied by the agar dilution checkerboard technique. The combination of bismuth subcitrate with the older quinolone, oxolinic acid, produced synergistic activity against all strains. This observation, however, could not be extended to the (aryl) fluoroquinolones, norfloxacin, ofloxacin, and difloxacin, since synergy was rare or absent when bismuth subcitrate was combined with these antibiotics. Among the other antimicrobial agents tested, rifampin and the beta-lactams frequently showed showed MICs for C. pyloridis similar to those of bismuth subcitrate.

Citing Articles

In Vitro Susceptibility and Synergistic Effect of Bismuth Against .

Woo J, Bang C, Lee J, Ahn J, Kim J, Jung H Antibiotics (Basel). 2024; 13(11).

PMID: 39596699 PMC: 11591412. DOI: 10.3390/antibiotics13111004.

Optimization Strategies Aimed to Increase the Efficacy of Eradication Therapies with Quinolones.

Gisbert J Molecules. 2020; 25(21).

PMID: 33147814 PMC: 7663000. DOI: 10.3390/molecules25215084.

Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant .

Krzyzek P, Paluch E, Gosciniak G Antibiotics (Basel). 2020; 9(10).

PMID: 33007899 PMC: 7599531. DOI: 10.3390/antibiotics9100658.

Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.

Jones K, Cha J, Merrell D Curr Drug ther. 2011; 3(3):190-203.

PMID: 21765819 PMC: 3136193. DOI: 10.2174/157488508785747899.

The action of bismuth against Helicobacter pylori mimics but is not caused by intracellular iron deprivation.

Bland M, Ismail S, Heinemann J, Keenan J Antimicrob Agents Chemother. 2004; 48(6):1983-8.

PMID: 15155188 PMC: 415606. DOI: 10.1128/AAC.48.6.1983-1988.2004.

References
1.
Gounot A, Brevet C, Videz S . [Nitrofurans: mode of action (author's transl)]. Ann Pharm Fr. 1979; 37(9-10):421-8. View
2.
McNulty C, Dent J, Wise R . Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother. 1985; 28(6):837-8. PMC: 180341. DOI: 10.1128/AAC.28.6.837. View
3.
Marshall B . Campylobacter pyloridis and gastritis. J Infect Dis. 1986; 153(4):650-7. DOI: 10.1093/infdis/153.4.650. View
4.
Van Caekenberghe D, PATTYN S . Reversed incomplete cross-resistance among the older and newer quinolone antibiotics. J Antimicrob Chemother. 1987; 19(3):404. DOI: 10.1093/jac/19.3.404. View
5.
Goodwin C, Blake P, Blincow E . The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrob Chemother. 1986; 17(3):309-14. DOI: 10.1093/jac/17.3.309. View